Company Encyclopedia
View More
name
HILE
603718.SH
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent products, and related diagnostic kits, including matrix metalloproteinase 3, IV collagen, adiponectin, creatine kinase isoenzyme, hepatic bile acid, cardiac troponin I, heparin binding protein, hemoglobin A1C, lipoprotein phospholipase A2, heart fatty acid binding protein, ferritin, sialoglycoside antigen, and procalcitonin kits.
3.095 T
603718.SHMarket value -Rank by Market Cap -/-

Financial Score

29/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking64/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE12.21%B
    • Profit Margin69.55%A
    • Gross Margin65.85%A
  • Growth ScoreB
    • Revenue YoY11.70%B
    • Net Profit YoY1953.15%A
    • Total Assets YoY11.06%B
    • Net Assets YoY38.48%A
  • Cash ScoreC
    • Cash Flow Margin143.78%C
    • OCF YoY11.70%B
  • Operating ScoreE
    • Turnover0.14E
  • Debt ScoreA
    • Gearing Ratio5.88%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    HILE: The transaction price for the major asset purchase has been adjusted to 536 million yuan

    HILE announced that it has signed a supplementary agreement with Meilun Management Co., Ltd. to adjust the transaction price for the major asset purchase to 536 million yuan. According to the assessment, the equity value of Ruisheng Bio has been revised down from 1.7 billion yuan to 974 million yuan, and the transaction price has been adjusted from 935 million yuan to 536 million yuan, with Meilun Company returning the difference of 399 million yuan. This adjustment does not affect HILE's holding of 55% equity in Ruisheng Bio and reduces investment risk. The adjusted commitments for non-net profit for 2025 and 2026 are 50 million yuan and 58 million yuan, respectively

    Zhitong·
    SH
    603718
    -0.81%
    Zhitong·
    SH
    603718
    -0.81%

    HILE: The registration application for Class III medical devices of the holding subsidiary has been accepted

    HILE announced that its holding subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., recently received a medical device registration application acceptance notice issued by the National Medical Products Administration. The medical device is a natural bone repair material suitable for the repair of jawbone defects. The acceptance number is CQZ2501670, and the product category is Class III medical devices. The registration application has been accepted, and it will undergo subsequent review and approval processes, as well as certification. This product is a Class III medical device, and once approved for market launch, it will enrich Ruisheng Biotechnology's product line in the field of oral bone defect repair

    Zhitong·
    SH
    603718
    -0.81%
    Zhitong·
    SH
    603718
    -0.81%

    HILE: Bone repair material registration application accepted

    HILE announced that the registration application for bone repair materials of its holding subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., has been accepted by the National Medical Products Administration. This product is suitable for filling and repairing maxillofacial bone defects and alveolar bone defects, and is a key material in oral bone defect repair surgeries. The existing bone repair material products of Ruisheng Biotechnology will be supplemented, further enriching its product line. Currently, the product is still in the acceptance stage and is not expected to have a definitive impact on the company and Ruisheng Biotechnology's existing business and operating performance

    Zhitong·
    SH
    603718
    -0.81%
    Zhitong·
    SH
    603718
    -0.81%

    HILE released its semi-annual performance, with a net profit attributable to the parent company of 18.23 million yuan, a year-on-year increase of 20.56%

    According to the Zhitong Finance APP, HILE disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 110 million yuan, a year-on-year increase of 2.02%; net profit attributable to the parent company was 18.23 million yuan, a year-on-year increase of 20.56%; net profit excluding non-recurring gains and losses was 15.47 million yuan, turning from loss to profit; basic earnings per share were 0.0282 yuan

    Zhitong·
    SH
    603718
    -0.81%
    Zhitong·
    SH
    603718
    -0.81%

    The animal vaccine sector continues to rise, with Shen Lian Biomedical up over 10%

    The animal vaccine sector continues to rise, with Shen Lian Biomedical up over 10%, and SDKX, Jinhe Biotechnology, Vland Biotech, Kanghua Biological, and HILE also following suit

    Zhitong·
    SZ
    002688
    -1.32%
    SH
    688098
    -0.22%
    SH
    603739
    -0.64%
    Zhitong·
    SZ
    002688
    -1.32%
    SH
    688098
    -0.22%
    SH
    603739
    -0.64%
    © 2025 Longbridge｜Disclaimer